Skip to main content
Midas Edge

Aldeyra Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

ALDX$0.63+2.9%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Consolidated Balance Sheets at June 30, 2026 (Unaudited) and December 31, 2025

CONSOLIDATED BALANCE SHEETS

June 30,
2026December 31,
(unaudited)2025
ASSETS
Current assets:
Cash and cash equivalents$45,089,786$70,041,254
Prepaid expenses and other current assets2,289,1201,742,202
Total current assets47,378,90671,783,456
Fixed assets, net20,544—
Right-of-use assets141,109275,861
Total assets$47,540,559$72,059,317
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$137,476$158,461
Accrued expenses3,374,3336,120,297
Current portion of debt—15,249,632
Operating lease liabilities143,447280,537
Deferred collaboration revenue6,000,0006,000,000
Total current liabilities9,655,25627,808,927
Total liabilities9,655,25627,808,927
Commitments and contingencies (Notes 3, 9, & 13)
Stockholders' equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding——
Common stock, voting, $0.001 par value; 150,000,000 authorized and 60,321,068 and 60,162,773 shares issued and outstanding, respectively60,32160,163
Additional paid-in capital530,685,127528,147,480
Accumulated deficit(492,860,145)(483,957,253)
Total stockholders’ equity37,885,30344,250,390
Total liabilities and stockholders’ equity$47,540,559$72,059,317
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.